Rivaroxaban
A direct oral anticoagulant that inhibits Factor Xa, used to prevent and treat blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Unlike warfarin, it requires no routine blood monitoring and has fewer food and drug interactions.
Molekularmasse
435,8820 g/mol
LogP
2,50
TPSA
116,00 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Direct Factor Xa inhibitor.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Direct Factor Xa inhibitor.
2D-Struktur
Cite this structure
Embed this structure
SMILES
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1
InChI
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
Molecular Formula
C19H18ClN3O5S
HBD / HBA
1 / 6
Rotierbare Bindungen
5
Schwere Atome
29
Combining rivaroxaban with clopidogrel substantially increases bleeding risk through simultaneous inhibition of factor Xa and platelet P2Y12 receptors.
Fluconazole markedly increases rivaroxaban exposure through dual inhibition of CYP3A4 and P-glycoprotein, substantially elevating bleeding risk.
Cyclosporine, a strong dual inhibitor of CYP3A4 and P-glycoprotein, substantially increases rivaroxaban exposure and bleeding risk.
Adding aspirin to rivaroxaban increases bleeding risk through additive antithrombotic effects; some indications (COMPASS trial) use this combination with careful patient selection.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A direct oral anticoagulant that inhibits Factor Xa, used to prevent and treat blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Unlike warfarin, it requires no routine blood monitoring and has fewer food and drug interactions.
Direct Factor Xa inhibitor.
Key pharmacokinetic parameters for Rivaroxaban: Half-life: 5-9 hours.
Yes, Rivaroxaban is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
Same Target
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL198362. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9875401. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rivaroxaban"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rivaroxaban/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rivaroxaban/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rivaroxaban/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rivaroxaban"></drugfyi-drug>